Toll-like receptors expressed in tumor cells: targets for therapy Li YuShangwu Chen Review 07 February 2008 Pages: 1271 - 1278
Anti-tumor activity and trafficking of self, tumor-specific T cells against tumors located in the brain Robert M. PrinsChengyi J. ShuLinda M. Liau Original Article 06 February 2008 Pages: 1279 - 1289
Tumor destruction using electrochemotherapy followed by CpG oligodeoxynucleotide injection induces distant tumor responses Stephan RouxClaire BernatCaroline Robert Original Article 08 February 2008 Pages: 1291 - 1300
Development of a Listeria monocytogenes based vaccine against prostate cancer Vafa ShahabiMariela Reyes-ReyesPaulo Maciag Original Article 14 February 2008 Pages: 1301 - 1313
Impact of IFNα2b upon pSTAT3 and the MEK/ERK MAPK Pathway in Melanoma Wenjun WangHoward D. EdingtonJohn M. Kirkwood Original Article 03 April 2008 Pages: 1315 - 1321
Experimental manipulations of afferent immune responses influence efferent immune responses to brain tumors Diana L. ThomasDavid M. KranzEdward J. Roy Original Article 16 February 2008 Pages: 1323 - 1333
High frequency of immature dendritic cells and altered in situ production of interleukin-4 and tumor necrosis factor-α in lung cancer R. B. BaleeiroL. B. AnselmoJ. A. M. Barbuto Original Article 20 February 2008 Pages: 1335 - 1345
Investigation of the mechanisms of tissue factor-mediated evasion of tumour cells from cellular cytotoxicity Chao LiMary E. W. CollierCamille Ettelaie Original Article 23 February 2008 Pages: 1347 - 1355
Fas-mediated T cell deletion potentiates tumor antigen-specific tolerance in a mouse model of prostate cancer Stephanie S. Tseng-RogenskiMohamed S. ArredouaniMartin G. Sanda Original Article 12 February 2008 Pages: 1357 - 1365
The role of extracellular matrix metalloproteinase inducer protein in prostate cancer progression Michele C. MadiganElizabeth A. KingsleyYong Li Original Article 14 February 2008 Pages: 1367 - 1379
CD54 is a surrogate marker of antigen presenting cell activation N. A. SheikhL. A. Jones Original Article 23 February 2008 Pages: 1381 - 1390
Danger signals and nonself entity of tumor antigen are both required for eliciting effective immune responses against HER-2/neu positive mammary carcinoma: implications for vaccine design Maciej KmieciakJohanna K. MoralesMasoud H. Manjili Original Article 16 February 2008 Pages: 1391 - 1398
TARC and RANTES enhance antitumor immunity induced by the GM-CSF-transduced tumor vaccine in a mouse tumor model Hiroyuki InoueMutsunori IgaKenzaburo Tani Original Article 20 February 2008 Pages: 1399 - 1411
Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers Antoun ToubajiMoujahed AchtarSamir N. Khleif Original Article 23 February 2008 Pages: 1413 - 1420
Second international conference on cancer vaccines/adjuvants/delivery for the next decade (CVADD): Heidelberg, Germany, 10–12 October 2007 V. SchirrmacherP. BeckhoveV. Umansky Meeting Report 13 February 2008 Pages: 1421 - 1427